Skip to content

Nerandomilast

Published: July 26, 2026Updated: July 26, 2026

Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially targets the PDE4B isoenzyme. By blocking PDE4, it prevents the breakdown of cyclic adenosine monophosphate (cAMP), which is involved in inflammatory pathways. This medication is being investigated for the treatment of inflammatory and immune-mediated conditions.

Quick summary

Nerandomilast is an investigational PDE4B-preferring inhibitor that modulates inflammatory responses by preventing cAMP breakdown.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

ATC
L04AA61
RxNorm
2725523
Generic
Nerandomilast
Class
atc-l04
Brands
Jascayd
Availability
rx
Lactation
unknown
Routes
oral
Forms
tablet
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Under investigation for inflammatory and immune-mediated conditions. PDE4 inhibitors like Nerandomilast are studied for conditions such as psoriasis, psoriatic arthritis, COPD, and other chronic inflammatory disorders.

Nerandomilast inhibits phosphodiesterase 4 (PDE4), particularly the PDE4B isoenzyme (with at least 9-fold preference over PDE4A, PDE4C, and PDE4D). This prevents the hydrolysis of cyclic adenosine monophosphate (cAMP), leading to increased intracellular cAMP levels that modulate inflammatory cell activity and cytokine production.

As an investigational agent, safety and efficacy profiles are being established through clinical trials. PDE4 inhibitors as a class are associated with gastrointestinal side effects such as nausea, diarrhea, and abdominal pain. Patients should use this medication only as prescribed in clinical trial settings until approved by regulatory authorities.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy